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Drug resistance mediating Plasmodium 
falciparum polymorphisms and clinical 
presentations of parasitaemic children 
in Uganda
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Abstract 
Background: Plasmodium falciparum genetic polymorphisms that mediate altered drug sensitivity may impact upon 
virulence. In a cross-sectional study, Ugandan children with infections mutant at pfcrt K76T, pfmdr1 N86Y, or pfmdr1 
D1246Y had about one-fourth the odds of symptomatic malaria compared to those with infections with wild type 
(WT) sequences. However, results may have been confounded by greater likelihood in those with symptomatic dis-
ease of higher density mixed infections and/or recent prior treatment that selected for WT alleles.
Methods: Polymorphisms in samples from paired episodes of asymptomatic and symptomatic parasitaemia in 114 
subjects aged 4–11 years were followed longitudinally in Tororo District, Uganda. Paired episodes occurred within 
3–12 months of each other and had no treatment for malaria in the prior 60 days. The prevalence of WT, mixed, and 
mutant alleles was determined using multiplex ligase detection reaction-fluorescent microsphere assays.
Results: Considering paired episodes in the same subject, the odds of symptomatic malaria were lower for infec-
tions with mutant compared to WT or mixed sequence at N86Y (OR 0.26, 95% CI 0.09–0.79, p = 0.018), but not K76T 
or D1246Y. However, symptomatic episodes (which had higher densities) were more likely than asymptomatic to be 
mixed (for N86Y OR 2.0, 95% CI 1.04–4.0, p = 0.036). Excluding mixed infections, the odds of symptomatic malaria 
were lower for infections with mutant compared to WT sequence at N86Y (OR 0.33, 95% CI 0.11–0.98, p = 0.046), 
but not the other alleles. However, if mixed genotypes were grouped with mutants in this analysis or assuming that 
mixed infections consisted of 50% WT and 50% mutant genotypes, the odds of symptomatic infection did not differ 
between infections that were mutant or WT at the studied alleles.
Conclusions: Although infections with only the mutant pfmdr1 86Y genotype were associated with symptomatic 
infection, this association could primarily be explained by greater parasite densities and therefore greater prevalence 
of mixed infections in symptomatic children. These results indicate limited association between the tested polymor-
phisms and risk of symptomatic disease and highlight the value of longitudinal studies for assessing associations 
between parasite factors and clinical outcomes.
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Background
Malaria, in particular infection caused by Plasmodium 
falciparum, remains an overwhelming problem in most 
of sub-Saharan Africa [1]. Malaria control is greatly lim-
ited by drug resistance. Resistance to a number of drugs 
is mediated in part by polymorphisms in two putative 
drug transporters, encoded by the pfcrt and pfmdr1 genes 
[2]. The pfcrt 76T mutation is the major mediator of 
resistance to chloroquine and amodiaquine [3]. Polymor-
phisms in pfmdr1 impact upon sensitivity to a number 
of drugs [4]. Considering polymorphisms that are com-
mon in Africa, the pfcrt 76T and pfmdr1 86Y and 1246Y 
mutations are associated with decreased sensitivity to 
chloroquine and amodiaquine, but these same mutations 
mediate increased sensitivity to lumefantrine and meflo-
quine [2, 5, 6].
The effects of drug resistance mediating genetic poly-
morphisms on the fitness and virulence of malaria para-
sites is of interest. Considering fitness, discontinuation of 
chloroquine for the treatment of malaria has led to dra-
matic changes in circulating parasites, with the return of 
chloroquine-sensitive pfcrt K76 wild type (WT) parasites 
and also of strong anti-malarial efficacy for chloroquine 
[7]. Clearly, chloroquine-sensitive parasites with WT 
sequence at pfcrt have a fitness advantage over resistant 
parasites. Considering pfmdr1, WT parasites outgrew 
those with three mutations, only one of which (1246Y) is 
common in Africa, in in  vitro competition experiments 
[8]. Following mixed clinical isolates in culture over time, 
modest fitness advantages appeared associated with the 
mutant 86Y and WT D1246 alleles [9]. In an area with 
seasonal malaria, the prevalence of parasites with mutant 
pfcrt 76T and pfmdr1 86Y sequences decreased during 
the low transmission season, when drug pressure is low-
est, implying a fitness advantage for WT parasites [10]. 
Overall, in most cases parasites with WT sequences in 
pfcrt and pfmdr1 have appeared to have a fitness advan-
tage over mutant parasites.
It is unclear if P. falciparum drug resistance-mediating 
polymorphisms also impact on parasite virulence, char-
acterized as the ability to cause symptomatic or severe 
disease. Studies from India [11] and Mali [12], but not 
Sudan [13] or Gabon [14], showed associations between 
presence of the pfcrt 76T mutation and severe malaria, 
but these associations may have been due to clinical pro-
gression after chloroquine treatment failure, rather than 
variations in parasite virulence. Previously, differences in 
genotypes between parasites causing symptomatic and 
asymptomatic infections were studied in samples from a 
cross-sectional study of children from Tororo, Uganda. 
Remarkably, children harbouring isolates with muta-
tions at pfcrt K76T, pfmdr1 N86Y, or pfmdr1 D1246Y 
had about one-fourth the odds of symptomatic malaria 
compared to those with WT parasites [15]. Similarly, 
in children in Benin, the prevalence of the pfmdr1 86Y 
mutation was significantly greater in asymptomatic 
compared to symptomatic infections, consistent with 
decreased virulence of parasites with the pfmdr1 86Y 
mutation [16]. However, the results of these case–con-
trol studies may have been confounded by two factors. 
First, infections associated with symptomatic disease 
typically have greater parasite densities than those that 
are asymptomatic, increasing the likelihood of detecting 
WT genotypes present in mixed infections. Second, chil-
dren with symptomatic infection may have had a greater 
likelihood, compared to children presenting with asymp-
tomatic infection, of a recent prior infection treated with 
artemether/lumefantrine, which selects for WT alleles 
[17–20]. To further explore relationships between para-
site genotype and clinical presentation, samples were uti-
lized from an ongoing longitudinal study and genotypes 
were compared for parasites in paired samples from 
Ugandan children with symptomatic and asymptomatic 
episodes of malaria.
Methods
Longitudinal study
Samples were collected from children enrolled in a 
cohort study in Nagongera Sub-county, Tororo District, 
Uganda, an area of high malaria transmission intensity. 
The cohort study has been described previously [21]. In 
brief, all households within the sub-county were enumer-
ated and mapped, and 100 randomly selected households 
were enrolled if they met enrollment criteria of having 
at least one resident 0.5–10 years of age and at least one 
adult who provided informed consent. Subjects were 
encouraged to visit a dedicated study clinic open seven 
days a week for any illnesses. Febrile subjects (tempera-
ture ≥38 °C tympanic or history of fever in the past 48 h) 
were evaluated at the clinic, and if malaria was diagnosed 
based on any level of parasitaemia on a Giemsa-stained 
thick smear, treatment (artemether–lumefantrine for 
uncomplicated malaria; quinine for complicated malaria) 
was provided. Subjects also had routine blood smears 
obtained every 3 months. At the time of blood collection 
either for symptomatic disease or at routine visits, blood 
was also spotted onto filter paper and stored. The cohort 
study was approved by the Makerere University School of 
Medicine Research and Ethics Committee, the Uganda 
National Council for Science and Technology, and the 
University of California, San Francisco Committee on 
Human Research.
Specimens evaluated for this study
For this sub-study, all subjects who met study crite-
ria were identified. No a priori power calculation was 
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performed for the sub-study. These subjects were aged 
4–11  years and had two smear positive specimens, one 
from an episode of symptomatic (with fever, defined as 
above) malaria and another from an episode of asymp-
tomatic parasitaemia, with each episode without prior 
treatment for malaria within 60  days, and the two epi-
sodes within 3–12 months of each other. These episodes 
all occurred between November, 2011 and December, 
2014. Samples from each episode were collected and 
studied.
Characterization of parasite polymorphisms
DNA was extracted from filter paper blood spots into 
100  μl of water using Chelex-100 [22]. Gene fragments 
spanning all loci of interest were amplified, and multiplex 
ligase detection reaction-fluorescent microsphere assays 
were performed as previously described [20, 23].
Statistical methods
Data analysis was done using R version 3.3 [24]. The pri-
mary outcome was presentation with symptomatic vs. 
asymptomatic malaria infection. Comparisons of the 
odds of genotypes present in symptomatic vs. asymp-
tomatic paired isolates was performed grouping mixed 
infections as mutant, mixed infections as WT, exclud-
ing mixed infections from the analysis, or considering 
mixed samples as consisting of 50% WT and 50% mutant 
parasites. Analyses were performed using a binomial 
generalized estimating equations model, to allow for cor-
relation between paired samples from each individual. A 
p value <0.05 was considered statistically significant.
Results
Characteristics of study subjects and episodes of malaria
Characteristics of the 114 subjects who provided sam-
ples for analysis and of the studied malaria infections 
are shown in Table  1. Similar numbers of children pre-
sented first with asymptomatic (54) compared to symp-
tomatic (60) infections, and the mean age of the children 
when they presented with asymptomatic vs. symptomatic 
infections was very similar. The mean parasite density 
was about fourfold higher in symptomatic compared to 
asymptomatic infections.
Prevalence of Plasmodium falciparum polymorphisms
Three P. falciparum polymorphisms that are associated 
with response to multiple anti-malarial drugs were stud-
ied [2]. All three of these mutations were previously very 
common in Ugandan isolates, but prevalence is decreas-
ing, presumably due to decreased usage of chloroquine 
and increased usage of artemether–lumefantrine to treat 
malaria in Uganda [20, 24, 25]. Considering all study 
samples, about half were pure WT for the pfmdr1 N86Y 
and D1246Y alleles, and  <10% were pure WT at pfcrt 
K76T (Table 2).
Considering paired episodes in the same subject, 
thus controlling for host factors, the odds of sympto-
matic malaria were significantly lower for infections 
with mutant compared to WT or mixed sequence at 
N86Y (OR 0.26, 95% CI 0.09–0.79, p =  0.018), but not 
the other alleles (pfmdr1 D1246Y OR 0.69, 95% CI 0.37–
1.28, p  =  0.24; pfcrt K76T OR 0.77, 95% CI 0.36–1.63, 
p  =  0.49). However, if mixed genotypes were grouped 
with mutants in this analysis, the odds of symptomatic 
malaria were similar for mutant and mixed N86Y geno-
types compared to pure WT (OR 1.23, 95% CI 0.72–2.10, 
p = 0.44). This difference was explained by the fact that 
symptomatic episodes were more likely than asympto-
matic to be mixed (for N86Y OR 2.0, 95% CI 1.04–4.0, 
p  =  0.036). Excluding mixed infections, the odds of 
symptomatic malaria were lower for infections with 
mutant compared to WT sequence at N86Y (OR 0.33, 
95% CI 0.11–0.98, p =  0.046), but not the other alleles 
(pfmdr1 D1246Y OR 0.82, 95% CI 0.46–1.43, p =  0.48; 
pfcrt K76T OR 1.08, 95% CI 0.43–2.75, p = 0.87). Assum-
ing arbitrarily that mixed infections consisted of 50% WT 
and 50% mutant genotypes, the odds of symptomatic 
infection was 0.89 (95% CI 0.56–1.41, p = 0.61) for infec-
tions mutant at pfmdr1 N86Y, 0.92 (95% CI 0.63–1.34, 
p =  0.66) for infections mutant at pfmdr1 D1246Y, and 
0.88 (95% CI 0.40–1.92, p = 0.75) for infections mutant 
at pfcrt K76T.
Discussion
The prevalence of three P. falciparum polymorphisms 
associated with drug resistance was compared in chil-
dren with either asymptomatic or symptomatic malaria 
Table 1 Characteristics of study children and paired malaria infections
For each child, paired asymptomatic and symptomatic infections were studied, regardless of which presentation occurred first. For duration between episodes, the 
times shown are means for episodes preceded by a prior episode in the other category
Characteristic Total episodes Asymptomatic episodes Symptomatic episodes
Number of episodes 228 114 114
Number with first presentation for each category 114 54 60
Age at time of sample collection (mean) (years) 7.00 7.02 6.98
Duration between episodes (mean) (days) 118 121 115
Parasite density (geometric mean) 9080/μl 3767/μl 14,390/μl
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infections in a cohort followed longitudinally in Tororo, 
Uganda. In 114 children with paired samples from epi-
sodes of asymptomatic and symptomatic malaria infec-
tions that occurred within a year, differences between 
genotypes of parasites from asymptomatic and sympto-
matic infections were much less marked than had been 
seen in prior case–control studies. One mutant geno-
type, pfmdr1 86Y, was more common in samples from 
asymptomatic compared to symptomatic infections, but 
symptomatic infections were more commonly mixed, 
potentially explaining the association. These results indi-
cate limited association between the tested polymor-
phisms and clinical outcomes.
Decreased prevalence of pfcrt 76T and pfmdr1 86Y and 
1246Y mutant genotypes in symptomatic, compared to 
asymptomatic infections was previously demonstrated in 
Ugandan children [15]. A study in Benin found a similar 
association for pfmdr1 86Y, but not pfcrt 76T [16]. These 
results suggested that these mutations render parasites 
less capable than WT parasites of causing clinical illness. 
However, the prior studies were case–control studies 
subject to confounding. First, children with symptomatic 
disease typically have greater parasite densities [15, 26], 
and thus a greater likelihood of detection of a mixed 
infection, than asymptomatic children. This was the case 
in the present study, with an odds ratio of 2.0 for mixed 
infections in symptomatic, compared to asymptomatic 
children. The increased prevalence of mixed infec-
tions likely at least partially explained the association 
between mutant genotypes and asymptomatic infection, 
as a greater likelihood of mixed infection would lead to 
a greater likelihood of WT parasites being identified in 
a symptomatic infection. In other words, symptomatic 
infections would be more likely than asymptomatic to 
have both WT and mutant parasites identified, thereby 
increasing the chance of WT being associated with symp-
tomatic infections. Second, children with symptomatic 
malaria in cross-sectional evaluation were probably more 
likely to have had a recent prior episode of malaria, and 
thus more likely to have received recent treatment with 
artemether-lumefantrine, which selects for WT geno-
types at the studied polymorphisms [17–20], and is the 
national first line regimen to treat malaria in Uganda 
and Benin [1]. In the present study, the influence of prior 
treatment was removed by studying only episodes with-
out prior treatment for malaria within 60 days.
This study was designed to limit confounding in the 
comparison of parasites causing asymptomatic and 
symptomatic malaria infections. Utilizing samples from a 
longitudinal study, prior treatment histories were known, 
and only samples without prior therapy within 60  days, 
approximately the duration of selective pressure on the 
studied genotypes of artemether–lumefantrine, were 
studied [19]. To limit differences related to host immu-
nity, only children over 4  years of age were studied; in 
this area of very high transmission intensity, children 
of this age would be expected to all have had numerous 
prior malaria exposures. To limit differences related to 
host factors, analysis of matched samples from the same 
patient was performed; roughly equal numbers of sam-
ples were from asymptomatic infections that occurred 
before or after symptomatic infections. With this study 
design, associations between parasite genotypes and clin-
ical presentation were much less pronounced than seen 
previously in cross-sectional studies.
This study had some limitations. The sample size was 
necessarily limited by strict criteria for inclusion of 
samples for analysis, and so there may have been inad-
equate power to identify associations of small magni-
tude. The molecular assays had limited sensitivity, and 
so some minority genotypes that might play a role in 
disease presentation may have been missed. Of note, the 
molecular methods differed from those used in an earlier 
cross-sectional analysis in Uganda, but the two methods 
(restriction fragment length polymorphism analysis and 
multiplex ligase detection reaction-fluorescent micro-
sphere analysis) have similar sensitivities [23]. Despite 
these limitations, use of longitudinal samples, with 
Table 2 Prevalence of P. falciparum polymorphisms of  interest in children with symptomatic and asymptomatic parasi-
taemia
SNP Genotype Total number (%) Symptomatic (%) Asymptomatic (%)
pfmdr1 N86Y Wild type 140 (64) 67 (61) 73 (66)
Mixed 63 (29) 39 (35) 24 (22)
Mutant 17 (7.7) 4 (4) 13 (12)
pfmdr1 D1246Y Wild type 98 (46) 47 (45) 51 (47)
Mixed 69 (32) 38 (36) 31 (28)
Mutant 48 (22) 20 (19) 28 (25)
pfcrt K76T Wild type 14 (6.5) 7 (6) 7 (7)
Mixed 8 (3.7) 6 (5) 2 (2)
Mutant 193 (90) 99 (89) 94 (91)
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comparisons of samples from the same children, offered 
a valuable means of considering the impact of parasite 
genotypes on clinical presentation.
Conclusions
Comparing two episodes of malaria parasitaemia in the 
same child with a design that limited influences of prior 
malaria treatment and varied prevalence of mixed infec-
tion, studied drug resistance genotypes had modest, if 
any influence on the risk of symptomatic malaria. Fur-
ther studies of the impacts of parasite genetic polymor-
phisms on P. falciparum fitness and virulence are needed. 
These results highlight the value of longitudinal samples 
from well-studied subjects to answer questions concern-
ing associations between parasite factors and clinical 
outcomes.
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